Show simple item record

dc.contributor.authorAbed, Howraa
dc.contributor.authorBall, Patrick
dc.contributor.authorMorrissey, Hana
dc.date.accessioned2017-08-10T13:24:56Z
dc.date.available2017-08-10T13:24:56Z
dc.date.issued2017-07-05
dc.identifier.citationAbed, H., Ball, P. and Morrissey, H. (2017) 'Barriers to early detection of cognitive impairment in the elderly despite the availability of simple cognitive screening tools and the pharmacist's role in early detection and referral' Journal of Pharmacy Practice and Research, 47, pp. 287–293 doi:10.1002/jppr.1252
dc.identifier.issn1445-937X
dc.identifier.doi10.1002/jppr.1252
dc.identifier.urihttp://hdl.handle.net/2436/620578
dc.description.abstractAim The aim of this review is to identify a suitable cognitive screening tool that can be used by the pharmacist during home medication review in addition to calculating the medications’ total anticholinergic burden (ACB). Data sources A search of the literature was conducted using PubMed, Embase, Medline and Google Scholar databases to identify relevant studies using the following keywords: ‘cognitive impairment’, ‘cognitive impairment AND diagnosis’, ‘cognitive scales’, ‘dementia’, ‘delirium’, ‘pharmacist role’, ‘mini-mental state examination (MMSE)’, ‘the Rowland dementia assessment scale (RUDAS)’, ‘the Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog)’ and ‘barriers and problems’. Only informational websites, clinical trials and review articles were included. Results The MMSE, RUDAS, ADAS-Cog, Psychogeriatric Assessment Scale (PAS) and Kimberley Indigenous Cognitive Assessment (KICA-Cog) require specialist training. The anxiety and depression checklist (K10) and ‘worried about your memory’ (WAYM) can be self-administered without prior training. The ACB scoring system can also be used to determine the total medications ACB. Conclusion The K10 and WAYM can be used by the pharmacist during medication reviews to detect cognitive impairment early and refer the elderly for further medical care supported by the calculated score for the patient‘s total medications‘ ACB.
dc.language.isoen
dc.publisherSociety of Hospital Pharmacists of Australia available via Wiley Online Library
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1002/jppr.1252/abstract;jsessionid=12F81B77CCBE93C496170D67581145E6.f02t01?systemMessage=Wiley+Online+Library+will+be+unavailable+on+Saturday+12th+August+at+3%3A00+EDT+%2F+8%3A00+BST+%2F+12%3A30+IST+%2F+15%3A00+SGT+for+4+hours+for+essential+maintenance.+Apologies+for+the+inconvenience.
dc.subjectcognitive impairment
dc.subjectcognitive screening tests
dc.subjectpharmacist’s role
dc.subjectmedication review
dc.titleBarriers to early detection of cognitive impairment in the elderly despite the availability of simple cognitive screening tools and the pharmacist’s role in early detection and referral
dc.typeJournal article
dc.identifier.journalJournal of Pharmacy Practice and Research
dc.date.accepted2017-01-01
rioxxterms.funderJisc
rioxxterms.identifier.projectUoW100817HM
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/CC BY-NC-ND 4.0
rioxxterms.licenseref.startdate2019-02-01
dc.source.volume47
dc.source.issue4
dc.source.beginpage287
dc.source.endpage293
refterms.dateFCD2018-10-19T09:24:44Z
refterms.versionFCDAM
refterms.dateFOA2018-12-05T12:12:20Z
html.description.abstractAim The aim of this review is to identify a suitable cognitive screening tool that can be used by the pharmacist during home medication review in addition to calculating the medications’ total anticholinergic burden (ACB). Data sources A search of the literature was conducted using PubMed, Embase, Medline and Google Scholar databases to identify relevant studies using the following keywords: ‘cognitive impairment’, ‘cognitive impairment AND diagnosis’, ‘cognitive scales’, ‘dementia’, ‘delirium’, ‘pharmacist role’, ‘mini-mental state examination (MMSE)’, ‘the Rowland dementia assessment scale (RUDAS)’, ‘the Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog)’ and ‘barriers and problems’. Only informational websites, clinical trials and review articles were included. Results The MMSE, RUDAS, ADAS-Cog, Psychogeriatric Assessment Scale (PAS) and Kimberley Indigenous Cognitive Assessment (KICA-Cog) require specialist training. The anxiety and depression checklist (K10) and ‘worried about your memory’ (WAYM) can be self-administered without prior training. The ACB scoring system can also be used to determine the total medications ACB. Conclusion The K10 and WAYM can be used by the pharmacist during medication reviews to detect cognitive impairment early and refer the elderly for further medical care supported by the calculated score for the patient‘s total medications‘ ACB.


Files in this item

Thumbnail
Name:
Barriers to early detection of ...
Size:
593.2Kb
Format:
PDF
Thumbnail
Name:
Barriers to early detection of ...
Size:
593.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/CC BY-NC-ND 4.0